Batu Biologics Appoints Alan Lewis to Chairman of the Board

Batu Biologics Appoints Biopharmaceutical Executive Dr. Alan Lewis as Chairman of the Board

World Class Industry Expert to Accelerate Development of Cancer Immunotherapeutic Platform after IND Filing for Lung Cancer Indication

Batu Biologics, a San Diego biotechnology company dedicated towards the development of its cancer angiogenesis-targeting immunotherapeutic product, ValloVax, announced today the appointment of Dr. Alan Lewis as Chairman of the Board of Directors.

Read the full article at businesswire.com

Continue →
0

Startup applies to test cancer therapy

Batu Biologics, a year-old startup, has filed to begin a clinical trial of its cancer vaccine, which seeks to harness the immune system to stop growth of new blood vessels that feed tumors.

The San Diego startup said Thursday that its therapy, ValloVax™, will be tested in a Phase 1/2 trial against non-small cell lung cancer once the U.S. Food and Drug Administration approves the application.

ValloVax™ targets proteins found in blood vessels induced by cancer that are not present in ordinary ...

Continue →
0

Bringing Innovative Weapons To the Cancer Battlefront

What if we could engineer “killer cells” to wage war on tumors, and then program the little soldiers to seek a specific kill zone? What if glowing tumors could tell doctors which tissue material to remove during surgery?

These are just two of the recent breakthroughs in cancer research being undertaken by the hundreds of local bio- tech firms that are pumping money and resources into the oncology market — a market that’s booming with players, ...

Continue →
0

Startup Conducts Unusual Funding ‘Experiment’

A local biotech startup and its 22 year old CEO — with support of local industry veterans — are trying a no-strings-attached funding model to finance their research on a potential cancer vaccine.

“If we raise money at this point in the preclinical stages, the venture capitalists or investors are going to take a large portion of our shares,” President and CEO Samuel Wagner said. “If ...

Continue →
0